ATRA

Atara Biotherapeutics, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-16

Figures on this page computed 2026-11-08 05:59 UTC

Last close

7.96USD

Market data, 2026-11-05

ATRA: weekly closes from 11.81 on 2025-11-07 to 7.96 on 2026-11-05, a move of -32.6%. Prices in USD.

Weekly closes, 2025-11-07 to 2026-11-05

Over that span: -32.6%

Except where said otherwise: 10-K for 2025, filed 2026-03-16

3.0xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-108361
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-16
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-108361
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
- 10-Q for 2025, filed 2026-08-12
- 10-K for 2025, filed 2026-03-16
- 10-Q for 2025, filed 2026-08-12
The filing itself
27.1%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-108361
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
The filing itself
-42.2%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-108361
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-108361
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-Q for 2025, filed 2026-08-12
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Safety is the furthest below its sector's middle: 0.27 against 0.53 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.50x

-0.17x

0.31x

n/a

0.03x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-05

Each against its own average

4 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-16

Sales1.50x
Its own average over 4 years, 80.5M.
Profit-0.17x
Its own average over 10 years, -192.4M.
Free cash flow0.31x
Its own average over 10 years, -163.3M.
Debtn/a
Its own average over 0 years.
Price0.03x
Its own average over 11 years, 302. Market data, 2026-11-05

Profit is furthest from its own average, at -0.17 times.

The filed years, as a table

Each line is 100 at 2020-12-31, the first year we hold.

Filed year	Sales	Shares in issue
2020-12-31	n/a	100.0
2021-12-31	n/a	126.6
2022-12-31	100.0	137.9
2023-12-31	13.5	143.2
2024-12-31	202.8	253.1
2025-12-31	190.0	429.8

How sales was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001193125-26-108361
Reported in: USD

The filing itself

How shares in issue was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001193125-26-108361
Reported in: USD

The filing itself

Figures behind the shape

Growth

138.3%

faster is higher, placed against 4,950 companies as of 2026-11-07

Five-year revenue growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
One-year change in net income138.3%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Returns on capital

161.5%

higher is higher, placed against 5,089 companies as of 2026-11-07

Return on invested capitaln/a
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-108361
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
- 10-Q for 2025, filed 2026-08-12
- 10-K for 2025, filed 2026-03-16
- 10-Q for 2025, filed 2026-08-12
The filing itself
Return on equityn/mnegative equity
Negative equity.
Net Income / Shareholders' Equity x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-108361
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-Q for 2025, filed 2026-08-12
The filing itself
Return on assets161.5%
Net Income / Total Assets x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-108361
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-Q for 2025, filed 2026-08-12
The filing itself

Margins

29.7%

wider is higher, placed against 3,412 companies as of 2026-11-07

Gross marginn/a
We do not hold this figure for this company, so there is nothing to place.
Gross Profit / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-108361
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
The filing itself
Operating margin29.7%
Operating Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-108361
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
The filing itself
Net margin27.1%
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-108361
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
The filing itself
Free cash flow margin-42.2%
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-108361
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
The filing itself

Price

3.0x

cheaper is higher, placed against 4,362 companies as of 2026-11-07

Price to earnings3.0x
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-108361
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-16
The filing itself
Price to bookn/a10-Q for 2025, filed 2026-08-12
We do not hold this figure for this company, so there is nothing to place.
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001193125-26-346885
Reported in
USD
- computed
- 10-Q for 2025, filed 2026-08-12
- computed
- 10-K for 2025, filed 2026-03-16
The filing itself
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-108361
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
- 10-Q for 2025, filed 2026-08-12
- 10-K for 2025, filed 2026-03-16
The filing itself
Price to sales ratio0.8x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001193125-26-108361
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
The filing itself

Safety

0.82

safer is higher, placed against 3,227 companies as of 2026-11-07

Debt to equityn/a
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-108361
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-Q for 2025, filed 2026-08-12
The filing itself
Current ratio0.8210-Q for 2025, filed 2026-08-12
Current Assets / Current Liabilities
Source
computed
Fiscal year
2025
Accession
0001193125-26-346885
Reported in
USD
- 10-Q for 2025, filed 2026-08-12
- 10-Q for 2025, filed 2026-08-12
The filing itself
Interest coverage9.5x
Operating Income / Interest Expense
Source
computed
Fiscal year
2025
Accession
0001193125-26-108361
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
The filing itself
Altman Z-Score-127.21
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-07
Reported in
USD
- Computed from the 10-K for 2025, filed 2026-03-16
- Computed from the 10-K for 2025, filed 2026-03-16
- Computed from the 10-K for 2025, filed 2026-03-16
- Computed from the 10-K for 2025, filed 2026-03-16
- Computed from the 10-K for 2025, filed 2026-03-16

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Fiscal year
2025
Accession
0001193125-26-108361
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- Computed from the 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
The filing itself
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.